Rigel Pharmaceuticals 미래 성장

Future 기준 확인 3/6

Rigel Pharmaceuticals (는) 각각 연간 4.6% 및 8.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 4.7% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 74.6% 로 예상됩니다.

주요 정보

4.6%

수익 성장률

-4.71%

EPS 성장률

Biotechs 수익 성장	23.9%
매출 성장률	8.6%
향후 자기자본 수익률	74.58%
애널리스트 커버리지	Good
마지막 업데이트	14 May 2025

최근 미래 성장 업데이트

Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 09

Recent updates

Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why

May 15

Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 09

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

May 07

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 02

Rigel Looks Interesting, But Let's Wait For A Lower Price

Mar 11

Advancing Pipeline And Partnerships Will Drive Future Success

Feb 09 Strong growth in the commercial portfolio is driven by increased demand and strategic expansions, especially with products like GAVRETO and TAVALISSE.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38%

Feb 06

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop

Dec 20

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Nov 08

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Oct 25

수익 및 매출 성장 예측

NasdaqGS:RIGL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	260	36	20	N/A	5
12/31/2026	233	36	32	N/A	6
12/31/2025	217	43	12	N/A	6
3/31/2025	203	37	35	36	N/A
12/31/2024	179	17	31	31	N/A
9/30/2024	157	4	10	11	N/A
6/30/2024	130	-14	-13	-12	N/A
3/31/2024	119	-20	-7	-7	N/A
12/31/2023	116	-25	-21	-6	N/A
9/30/2023	129	-24	-36	-21	N/A
6/30/2023	121	-38	-49	-33	N/A
3/31/2023	125	-45	-67	-52	N/A
12/31/2022	116	-59	-74	-74	N/A
9/30/2022	86	-83	-71	-71	N/A
6/30/2022	87	-85	-68	-68	N/A
3/31/2022	77	-85	-1	0	N/A
12/31/2021	139	-18	5	6	N/A
9/30/2021	138	-15	8	9	N/A
6/30/2021	136	-8	-1	0	N/A
3/31/2021	131	-11	-70	-69	N/A
12/31/2020	109	-30	-53	-52	N/A
9/30/2020	106	-28	-48	-46	N/A
6/30/2020	108	-25	-43	-41	N/A
3/31/2020	102	-28	-46	-44	N/A
12/31/2019	59	-67	-43	-42	N/A
9/30/2019	82	-46	-21	-20	N/A
6/30/2019	66	-59	-26	-26	N/A
3/31/2019	57	-64	-37	-36	N/A
12/31/2018	45	-70	N/A	-59	N/A
9/30/2018	7	-100	N/A	-90	N/A
6/30/2018	3	-93	N/A	-88	N/A
3/31/2018	1	-87	N/A	-80	N/A
12/31/2017	4	-78	N/A	-78	N/A
9/30/2017	7	-68	N/A	-70	N/A
6/30/2017	10	-73	N/A	-75	N/A
3/31/2017	19	-67	N/A	-74	N/A
12/31/2016	20	-69	N/A	-76	N/A
9/30/2016	26	-66	N/A	-77	N/A
6/30/2016	35	-50	N/A	-64	N/A
3/31/2016	32	-51	N/A	-64	N/A
12/31/2015	29	-51	N/A	-23	N/A
9/30/2015	29	-61	N/A	-25	N/A
6/30/2015	16	-75	N/A	-34	N/A
3/31/2015	10	-87	N/A	-35	N/A
12/31/2014	8	-91	N/A	-70	N/A
9/30/2014	6	-85	N/A	-74	N/A
6/30/2014	6	-88	N/A	-76	N/A

애널리스트 미래 성장 예측

수입 대 저축률: RIGL 의 연간 예상 수익 증가율( 4.6% )이 saving rate( 2.8% 보다 높습니다. ).

수익 vs 시장: RIGL 의 연간 수익( 4.6% ) US 시장( 14.3% 보다 느리게 성장할 것으로 예상됩니다. 14.3% 연간).

고성장 수익: RIGL 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: RIGL 의 수익(연간 8.6% ) US 시장( 8.5% 보다 빠르게 성장할 것으로 예상됩니다. 8.5% 연간).

고성장 수익: RIGL 의 수익(연간 8.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: RIGL 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 74.6 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/19 14:00
장 마감 주가	2025/05/19 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Rigel Pharmaceuticals, Inc. 26 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
James Birchenough	Barclays
Clarence Powell	BMO Capital Markets Equity Research
James Birchenough	BMO Capital Markets Equity Research

Rigel Pharmaceuticals 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates fall by 10%

Consensus revenue estimates increase by 11%

Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Rigel Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2025

Price target increased by 7.1% to US$32.67

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2025

Recent updates

Consensus EPS estimates fall by 10%

Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why

Consensus revenue estimates increase by 11%

Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum

Rigel Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2025

Rigel Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 06, 2025

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2025

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%

Rigel Looks Interesting, But Let's Wait For A Lower Price

Rigel Pharmaceuticals, Inc. Appoints Mark W. Frohlich, M.D. to Board of Directors

New minor risk - Financial position

Full year 2024 earnings released

Price target increased by 7.1% to US$32.67

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2025

Rigel Pharmaceuticals, Inc. to Report Fiscal Year 2024 Results on Mar 04, 2025

Advancing Pipeline And Partnerships Will Drive Future Success

President recently sold US$200k worth of stock

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38%

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Consensus EPS estimates increase by 43%

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2025

Insufficient new directors

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop

Price target increased by 7.4% to US$31.33

Rigel Pharmaceuticals, Inc. Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Price target increased by 7.2% to US$28.67

Now 68% overvalued after recent price rise

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Rigel Pharmaceuticals, Inc. Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Price target increased by 34% to US$26.75

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2024

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$0.43 loss

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application

Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress

Insufficient new directors

Consensus EPS estimates upgraded to US$0.062 loss

Consensus EPS estimates upgraded to US$0.073 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target increased by 14% to US$5.08

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Consensus EPS estimates fall by 13%

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

President recently sold US$60k worth of stock

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

No longer forecast to breakeven

New minor risk - Share price stability

Forecast to breakeven in 2025

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC